CN102525909A - 盐酸戊乙奎醚注射液的制备方法 - Google Patents
盐酸戊乙奎醚注射液的制备方法 Download PDFInfo
- Publication number
- CN102525909A CN102525909A CN2012100495931A CN201210049593A CN102525909A CN 102525909 A CN102525909 A CN 102525909A CN 2012100495931 A CN2012100495931 A CN 2012100495931A CN 201210049593 A CN201210049593 A CN 201210049593A CN 102525909 A CN102525909 A CN 102525909A
- Authority
- CN
- China
- Prior art keywords
- injection
- ether hydrochloride
- amyl ethyl
- ethyl quin
- quin ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 70
- 239000007924 injection Substances 0.000 title claims abstract description 70
- 238000000034 method Methods 0.000 title claims abstract description 33
- DDTVVMRZNVIVQM-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-1-cyclopentyl-1-phenylethanol;hydrochloride Chemical compound Cl.C1N(CC2)CCC2C1OCC(O)(C=1C=CC=CC=1)C1CCCC1 DDTVVMRZNVIVQM-UHFFFAOYSA-N 0.000 title abstract 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 94
- 239000008215 water for injection Substances 0.000 claims abstract description 89
- 239000007788 liquid Substances 0.000 claims abstract description 58
- 238000005303 weighing Methods 0.000 claims abstract description 36
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- 238000001035 drying Methods 0.000 claims abstract description 27
- 238000003756 stirring Methods 0.000 claims abstract description 5
- -1 amyl ethyl Chemical group 0.000 claims description 134
- LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 claims description 132
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 46
- 239000003708 ampul Substances 0.000 claims description 45
- 238000005374 membrane filtration Methods 0.000 claims description 35
- 238000004140 cleaning Methods 0.000 claims description 26
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 15
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 7
- 239000011521 glass Substances 0.000 claims description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 229910017604 nitric acid Inorganic materials 0.000 claims description 5
- 235000006408 oxalic acid Nutrition 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 28
- 241001465754 Metazoa Species 0.000 abstract description 23
- 238000012360 testing method Methods 0.000 abstract description 19
- 230000001105 regulatory effect Effects 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 231100001252 long-term toxicity Toxicity 0.000 abstract description 6
- 238000007789 sealing Methods 0.000 abstract description 6
- 239000005022 packaging material Substances 0.000 abstract description 4
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 4
- 239000000047 product Substances 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000011049 filling Methods 0.000 abstract 1
- 239000000706 filtrate Substances 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 239000012467 final product Substances 0.000 abstract 1
- 238000009928 pasteurization Methods 0.000 abstract 1
- 239000008213 purified water Substances 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 description 50
- 238000004659 sterilization and disinfection Methods 0.000 description 45
- 239000000523 sample Substances 0.000 description 30
- 238000005070 sampling Methods 0.000 description 22
- 238000005516 engineering process Methods 0.000 description 21
- 230000001133 acceleration Effects 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 14
- 210000002216 heart Anatomy 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 238000010255 intramuscular injection Methods 0.000 description 10
- 239000007927 intramuscular injection Substances 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 7
- 210000000232 gallbladder Anatomy 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000008354 sodium chloride injection Substances 0.000 description 5
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000812 cholinergic antagonist Substances 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000010562 histological examination Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000001747 pupil Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000009101 premedication Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- NPUIQANQRDIHLU-UHFFFAOYSA-N 3-(4-chlorophenyl)sulfonylbutanoic acid Chemical compound OC(=O)CC(C)S(=O)(=O)C1=CC=C(Cl)C=C1 NPUIQANQRDIHLU-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 208000007964 Organophosphate Poisoning Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004594 appetite change Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960001473 sulfobromophthalein sodium Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000009603 uroscopy Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210049593 CN102525909B (zh) | 2012-02-29 | 2012-02-29 | 盐酸戊乙奎醚注射液的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210049593 CN102525909B (zh) | 2012-02-29 | 2012-02-29 | 盐酸戊乙奎醚注射液的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102525909A true CN102525909A (zh) | 2012-07-04 |
CN102525909B CN102525909B (zh) | 2013-01-23 |
Family
ID=46334743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201210049593 Active CN102525909B (zh) | 2012-02-29 | 2012-02-29 | 盐酸戊乙奎醚注射液的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102525909B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103271872A (zh) * | 2013-05-14 | 2013-09-04 | 成都自豪药业有限公司 | 盐酸戊乙奎醚注射液的工业化生产方法 |
CN107638383A (zh) * | 2016-07-21 | 2018-01-30 | 王琴 | 盐酸戊乙奎醚注射液的制备工艺 |
CN112716889A (zh) * | 2020-12-25 | 2021-04-30 | 武汉大安制药有限公司 | 一种盐酸戊乙奎醚注射液的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1739516A (zh) * | 2002-08-16 | 2006-03-01 | 成都力思特制药股份有限公司 | 盐酸戊乙奎醚在制药中的应用 |
CN101474178A (zh) * | 2009-01-15 | 2009-07-08 | 成都力思特制药股份有限公司 | 盐酸戊乙奎醚在制备治疗心源性休克疾病药物中的应用 |
-
2012
- 2012-02-29 CN CN 201210049593 patent/CN102525909B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1739516A (zh) * | 2002-08-16 | 2006-03-01 | 成都力思特制药股份有限公司 | 盐酸戊乙奎醚在制药中的应用 |
CN101474178A (zh) * | 2009-01-15 | 2009-07-08 | 成都力思特制药股份有限公司 | 盐酸戊乙奎醚在制备治疗心源性休克疾病药物中的应用 |
Non-Patent Citations (1)
Title |
---|
张传勇: "盐酸戊乙奎醚注射液(长托宁)的临床应用", 《海峡药学》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103271872A (zh) * | 2013-05-14 | 2013-09-04 | 成都自豪药业有限公司 | 盐酸戊乙奎醚注射液的工业化生产方法 |
CN103271872B (zh) * | 2013-05-14 | 2016-05-11 | 成都自豪药业有限公司 | 盐酸戊乙奎醚注射液的工业化生产方法 |
CN107638383A (zh) * | 2016-07-21 | 2018-01-30 | 王琴 | 盐酸戊乙奎醚注射液的制备工艺 |
CN112716889A (zh) * | 2020-12-25 | 2021-04-30 | 武汉大安制药有限公司 | 一种盐酸戊乙奎醚注射液的制备方法 |
CN112716889B (zh) * | 2020-12-25 | 2022-05-06 | 远大生命科学(武汉)有限公司 | 一种盐酸戊乙奎醚注射液的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102525909B (zh) | 2013-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109453212B (zh) | 一种具有抗癌作用的毛诃子提取物及其有效部位制备方法 | |
CN103463565B (zh) | 一种莪术油注射液及其制备方法 | |
CN102525909B (zh) | 盐酸戊乙奎醚注射液的制备方法 | |
CN102366401A (zh) | 利巴韦林注射液及其生产工艺 | |
CN103040740A (zh) | 一种奥硝唑注射液及制备工艺 | |
CN105125566B (zh) | 甘露葡萄糖醛酸寡糖及衍生物在制备治疗和/或预防肾病药物或保健品中的应用 | |
CN102525910B (zh) | 盐酸戊乙奎醚注射液的制备工艺 | |
CN103284943A (zh) | 一种盐酸戊乙奎醚注射液的新型制备方法 | |
CN105663035A (zh) | 一种盐酸利多卡因注射液及其制备方法 | |
CN102872462B (zh) | 一种盐酸氨溴索组合物及其制剂 | |
US20190038667A1 (en) | Application of fullerene/metal-fullerene for preparing pharmaceutical product | |
KR20150056586A (ko) | 테트란드린 제약 제제 및 방법 | |
CN101081250B (zh) | 一种改善贫血的何首乌提取物药剂及其制备方法和应用 | |
CN101904856A (zh) | 1,6-二磷酸果糖及其衍生物在制备动物医疗保健品中的应用 | |
CN107157924A (zh) | 萘普生钠氯化钠注射液及其制备方法 | |
CN101212963A (zh) | 绿原酸在制备具有增加骨髓细胞功效的药物中的用途 | |
Huber et al. | In line final filters for removing particles from amphotericin B infusions | |
CN102988281A (zh) | 一种盐酸氨溴索的注射液及其制备方法 | |
CN102552210B (zh) | 一种恩替卡韦胶囊组合物及其制备方法 | |
CN107334729B (zh) | 一种单唾液酸四己糖神经节苷脂钠口服液及其用途 | |
CN112386600B (zh) | 湖贝甲素在制备预防急性肾损伤药物中的用途 | |
CN117137902B (zh) | (-)-驴食草酚在制备预防和/或治疗阿尔茨海默病的药物中的用途 | |
CN102525911B (zh) | 一种溴甲纳曲酮注射液及其制备方法 | |
CN108653301B (zh) | 糖苷类化合物在制备防治糖尿病并发症的药物中的应用 | |
CN110507614B (zh) | miR#4脂质体药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120704 Assignee: Chengdu Lisite Pharmaceutical Co., Ltd. Assignor: Huang Shaoyuan|Zhang Hao|Jin Hongdi|Liu Xinchun|Zhu Dengjun Contract record no.: 2015510000011 Denomination of invention: Method for preparing penehyclidine hydrochloride injection Granted publication date: 20130123 License type: Exclusive License Record date: 20150303 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Chengdu Lisite Pharmaceutical Co., Ltd. Assignor: Huang Shaoyuan|Zhang Hao|Jin Hongdi|Liu Xinchun|Zhu Dengjun Contract record no.: 2015510000011 Date of cancellation: 20150312 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180510 Address after: 610000 Jinjiang Industrial Development Zone, Chengdu, Sichuan Patentee after: Chengdu Lisite Pharmaceutical Co., Ltd. Address before: No. 47, red ball dam, Yuzhong District, Chongqing, Chongqing Co-patentee before: Zhang Hao Patentee before: Huang Shaoyuan Co-patentee before: Jin Hongdi Co-patentee before: Liu Xinchun Co-patentee before: Zhu Dengjun |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200519 Address after: 121013 Songshan street, Taihe District, Jinzhou, Liaoning Province, No. 55 Patentee after: SHANGHAI FOCHON PHARMACEUTICAL Co.,Ltd. Address before: 610000 Jinjiang Industrial Development Zone, Sichuan, Chengdu Patentee before: CHENGDU LIST PHARMACEUTICAL Co.,Ltd. |